# Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

> **NCT05577442** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 52 (estimated)

## Conditions studied

- Breast Neoplasm Female

## Interventions

- **DRUG:** Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy

## Key facts

- **NCT ID:** NCT05577442
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-20
- **Primary completion:** 2023-10-20
- **Final completion:** 2024-10-20
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577442, "Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05577442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*